Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Baclofen on Presynaptic Inhibition
NCT04471714Phase 2Withdrawn
- Sponsor
- University of Alberta
- Start
- Jan 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baclofen in spasticity and spinal cord injury (SCI) (2 arms), sponsored by University of Alberta. Primary endpoint: Effects of baclofen on Presynaptic Inhibition of primary afferents at 1 year. Planned start Jan 2020; status: withdrawn.
02
Drugs
baclofen
03
Conditions
spasticityspinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04471714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471714.